孕中期超声软指标胎儿是否应提供染色体微阵列分析:前瞻性队列研究及荟萃分析
该前瞻性队列研究纳入564例孕中期超声软指标胎儿,并荟萃分析约10项研究(405例轻度脑室扩张、1412例其他超声软指标)。轻度脑室扩张胎儿中CMA较NIPT和核型的诊断增益显著高于超声正常对照,其他超声软指标则与对照相似;作者认为轻度脑室扩张胎儿可提供CMA作为一线检测,其他超声软指标胎儿的CMA考虑不应不同于超声正常妊娠。
要点
- 轻度脑室扩张胎儿中CMA较NIPT和核型的诊断增益显著高于超声正常对照。
- 其他超声软指标胎儿中CMA较NIPT和核型的诊断增益与对照相似。
- 荟萃分析中轻度脑室扩张胎儿CMA较NIPT和核型的合并诊断增益分别为4.9%和3.2%。
核心结论
- 作者认为对轻度脑室扩张胎儿提供CMA作为一线检测是合理的。
- 作者认为对其他超声软指标胎儿,进行CMA的考虑不应不同于超声正常妊娠。
研究设计与样本
- 前瞻性队列研究纳入564例孕中期超声软指标胎儿。
- 荟萃分析纳入描述超声软指标胎儿拷贝数变异的合格文献,约10项研究涉及405例轻度脑室扩张胎儿和1412例其他超声软指标胎儿。
主要发现
- 前瞻性队列中,轻度脑室扩张胎儿CMA较NIPT和核型的诊断增益显著高于超声正常局部对照队列。
- 前瞻性队列中,其他超声软指标胎儿CMA较NIPT和核型的诊断增益与对照相似。
- 荟萃分析中,轻度脑室扩张胎儿CMA较NIPT和核型的合并诊断增益分别为4.9%和3.2%。
- 荟萃分析中,其他超声软指标胎儿CMA较NIPT和核型的诊断增益分别为1.2%和0.4%。
关键数值与推荐
- 轻度脑室扩张胎儿CMA较NIPT的合并诊断增益为4.9%,较核型的合并诊断增益为3.2%。
- 其他超声软指标胎儿CMA较NIPT的诊断增益为1.2%,较核型的诊断增益为0.4%。
临床怎么用
- 作者认为对轻度脑室扩张胎儿提供CMA作为一线检测是合理的。
- 作者认为对其他超声软指标胎儿,进行CMA的考虑不应不同于超声正常妊娠。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether chromosomal microarray (CMA) should be offered to fetuses with ultrasonographic soft markers (USMs) in the second trimester. METHODS: A prospective cohort study and meta-analysis were conducted. In the prospective cohort study, 564 fetuses with USMs were enrolled. In the meta-analysis, eligible articles describing copy number variations in fetuses with USMs were included. RESULTS: In the prospective cohort study, the diagnostic yields of CMA over non-invasive prenatal testing (NIPT) and karyotyping were significantly higher in fetuses with mild ventriculomegaly (MVM) than those in local control cohorts with normal ultrasound. However, the yields of CMA over NIPT and karyotyping in fetuses with other USMs were similar to controls. About ten studies, involving 405 fetuses with MVM and 1412 fetuses with other USMs, were included in the meta-analysis. The pooled diagnostic yields of CMA over NIPT and karyotyping in fetuses with MVM were 4.9% and 3.2%, respectively. In fetuses with other USMs, the yields of CMA over NIPT and karyotyping were 1.2% and 0.4%, respectively. CONCLUSION: It is reasonable to offer CMA as a first-tier test to fetuses with MVM. However, for fetuses with other USMs, the considerations to perform CMA should not differ from pregnancies with normal ultrasound.
引用
- Li S, Han X, Ye M, et al. Should chromosomal microarray be offered to fetuses with ultrasonographic soft markers in second trimester: A prospective cohort study and meta-analysis. Prenat Diagn. 2020. PMID: 32812229. doi:10.1002/pd.5815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。